RBRolf N. Barth

Rolf N. Barth

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rolf N. Barth has a total of 586 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Need for kidney transplantation following vascularized composite allotransplantation: an international, multi-center case series

    by J. Reed Mcgraw, Zachary Gala, Corey M. Bascone, Chris Amro, Annemarie Weissenbacher, Gerald Brandacher, Stefan Schneeberger, Mattias Kapturczak, Matthew H. Levine, Abraham Shaked, et al.

    Introduction: Vascularized composite allotransplantation (VCA) is a powerful restorative tool for patients with severe soft tissue loss. The long-term implications of immunosuppression following VCA on renal function remain uncertain. Methods: A retrospective review of patients undergoing VCA and requiring renal transplant at three global centers was performed. Renal and VCA graft function were monitored over time. Causes of renal failure and time to renal transplant following VCA were determined. Results: Three patients were included. Patient A underwent face transplantation, and patients B and C underwent bilateral hand transplantations. All patients were on tacrolimus therapy following VCA. Renal failure occurred in all patients: secondary to tacrolimus toxicity in patient A; on the grounds of biopsy proven pre-existing renal damage in patient B; and secondary to prior septic acute tubular necrosis plus tacrolimus toxicity in patient C. Living/deceased donor renal transplant was performed at 87, 7, and 107 months, respectively. Patient A has had progressive recipient kidney impairment (creatinine at last follow-up: 2.26 mg/dL). Patients B and C have had stable recipient kidney function (creatinine 0.89 mg/dL and 1.20 mg/dL). VCA graft function in the setting of renal failure was not altered. Conclusions: Nephrotoxicity and potential renal failure remain major issues following VCA, as demonstrated in this cohort of patients requiring renal replacement therapy and transplant. VCA graft function and survival in the setting of renal failure was not altered. Patients undergoing VCA should be appropriately counseled on the long-term renal implications of immunosuppression.

  • Open Access

    Comparing High- and Low-Model for End-Stage Liver Disease Living-Donor Liver Transplantation to Determine Clinical Efficacy: A Systematic Review and Meta-Analysis (CHALICE Study)

    by Kumar Jayant, Thomas G. Cotter, Isabella Reccia, Francesco Virdis, Mauro Podda, Nikolaos Machairas, Ramesh P. Arasaradnam, Diego di Sabato, John C. LaMattina, Rolf N. Barth, et al.

    Introduction: Various studies have demonstrated that low-Model for End-Stage Liver Disease (MELD) living-donor liver transplant (LDLT) recipients have better outcomes with improved patient survival than deceased-donor liver transplantation (DDLT) recipients. LDLT recipients gain the most from being transplanted at MELD p-value 0.40) and graft survival (HR 1.08; 95% CI 0.72, 1.63; p-value 0.71). No differences were observed in the rates of major morbidity, hepatic artery thrombosis, biliary complications, intra-abdominal bleeding, wound infection and rejection; however, the HM-LDLT group had higher risk for pulmonary infection, abdominal fluid collection and prolonged ICU stay. Conclusions: The high-MELD LDLT group had similar patient and graft survival and morbidities to the low-MELD LDLT group, despite being at higher risk for pulmonary infection, abdominal fluid collection and prolonged ICU stay. The data, primarily sourced from high-volume Asian centers, underscore the feasibility of living donations for liver allografts in high-MELD patients. Given the rising demand for liver allografts, it is sensible to incorporate these insights into U.S. transplant practices.


  • Open Access

    Persistence of long-term insulin independence after islet transplantation and two subsequent pregnancies

    by Sarah Gondek, Mateusz Ogledzinski, William Lin, Kamila Milejczyk, Braden Juengel, Lisa Potter, Piotr J. Bachul, Lindsay Basto, Laurencia Perea, Ling-Jia Wang, et al.

    Pregnancy increases metabolic demand for insulin and may lead to the exhaustion of intraportally transplanted islets and post-gestational hyperglycemia. To prevent these complications, we implemented preemptive insulin supplementation during two subsequent pregnancies in an insulin-independent islet transplant recipient. This strategy resulted in optimal blood glucose control during the pregnancies, the preservation of the optimal islet graft function and the postpartum maintenance of long-term insulin independence.


  • Peri‐operative Reparixin therapy resulted in 50% 5‐year insulin independence rate: The University of Chicago experience

    by Mateusz Ogledzinski, Piotr J. Bachul, Kourosh Rezania, Seenu M. Hariprasad, Sarah Gondek, William Lin, Braden Juengel, Kamila Milejczyk, Lindsay Basto, Ling‐Jia Wang, et al.


  • Open Access

    Review Paper on Penetrating Brain Injury

    by Tanya L. Zakrison, Rachael Essig, Ann Md Polcari, William McKinley, Damon Arnold, Robel Beyene, Kenneth Wilson, Selwyn Jr Rogers, Jeffrey B. Matthews, J. Michael Millis, et al.

    Objective: The aim of this review was to review the ethical and multidisciplinary clinical challenges facing trauma surgeons when resuscitating patients presenting with penetrating brain injury (PBI) and multicavitary trauma. Background: While there is a significant gap in the literature on managing PBI in patients presenting with multisystem trauma, recent data demonstrate that resuscitation and prognostic features for such patients remains poorly described, with trauma guidelines out of date in this field. Methods: We reviewed a combination of recent multidisciplinary evidence-informed guidelines for PBI and coupled this with expert opinion from trauma, neurosurgery, neurocritical care, pediatric and transplant surgery, surgical ethics and importantly our community partners. Results: Traditional prognostic signs utilized in traumatic brain injury may not be applicable to PBI with a multidisciplinary team approach suggested on a case-by-case basis. Even with no role for neurosurgical intervention, neurocritical care, and neurointerventional support may be warranted, in parallel to multicavitary operative intervention. Special considerations should be afforded for pediatric PBI. Ethical considerations center on providing the patient with the best chance of survival. Consideration of organ donation should be considered as part of the continuum of patient, proxy and family-centric support and care. Community input is crucial in guiding decision making or protocol establishment on an institutional level. Conclusions: Support of the patient after multicavitary PBI can be complex and is best addressed in a multidisciplinary fashion with extensive community involvement.


  • Open Access

    The Impact of COVID-19 on Kidney Transplant Recipients in Pre-Vaccination and Delta Strain Era: A Systematic Review and Meta-Analysis

    by Kumar Jayant, Isabella Reccia, Piotr J. Bachul, Yaser Al-Salmay, Jordan S. Pyda, Mauro Podda, Angelica Perez-Gutierrez, Frank J. M. F. Dor, Yolanda Becker, Diego di Sabato, et al.

    Herein, we performed a meta-analysis of published clinical outcomes of corona virus disease 2019 (COVID-19) in hospitalized kidney transplant recipients. A systematic database search was conducted between December 1, 2019 and April 20, 2020. We analyzed 48 studies comprising 3137 kidney transplant recipients with COVID-19. Fever (77%), cough (65%), dyspnea (48%), and gastrointestinal symptoms (28%) were predominant on hospital admission. The most common comorbidities were hypertension (83%), diabetes mellitus (34%), and cardiac disease (23%). The pooled prevalence of acute respiratory distress syndrome and acute kidney injury were 58% and 48%, respectively. Invasive ventilation and dialysis were required in 24% and 22% patients, respectively. In-hospital mortality rate was as high as 21%, and increased to over 50% for patients in intensive care unit (ICU) or requiring invasive ventilation. Risk of mortality in patients with acute respiratory distress syndrome (ARDS), on mechanical ventilation, and ICU admission was increased: OR = 19.59, OR = 3.80, and OR = 13.39, respectively. Mortality risk in the elderly was OR = 3.90; however, no such association was observed in terms of time since transplantation and gender. Fever, cough, dyspnea, and gastrointestinal symptoms were common on admission for COVID-19 in kidney transplant patients. Mortality was as high as 20% and increased to over 50% in patients in ICU and required invasive ventilation.


  • Open Access

    Regulatory updates are needed to prevent the commercialization of islet transplantation in the United States

    by Piotr Witkowski, Rolf N. Barth, Anthony Japour, Gail Javitt, Jordan S. Pyda, Piotr J. Bachul, Eryk Nowicki, Camillo Ricordi, the “Islet for US Collaborative”


  • Open Access

    Vascularized Bone Marrow Cellular Depletion or Discontinuity Abrogates Protection of Vascularized Composite Allografts in Nonhuman Primates

    by Nicole Shockcor, Evan B. Buckingham, Wessam Mbbch Hassanein, Urmil Msc Dhru, Ali Khalifeh, Mehmet Uluer, Jhade Woodall, Philip Brazio, Cynthia Drachenberg, Arthur J. Nam, et al.

    Background.: Vascularized composite allografts (VCA) have demonstrated good clinical outcomes dependent on chronic immunosuppression. Previous work by our group and others supports that cotransplanted vascularized bone marrow (VBM) as a component of VCA offers immunologic protection to prolong graft survival. We aimed to characterize the requirements and potential mechanisms of VBM-mediated protection of VCA by modifying grafts through various strategies. Methods.: Experimental groups of mismatched cynomolgus macaque recipients received VCA transplants modified by the following approaches: heterotopic separation of the VCA and VBM components; T-cell depletion of either donor or recipient; irradiation of donor VCA; and infusion of donor bone marrow. All groups received standard immunosuppression with tacrolimus and mycophenolate mofetil. Results.: Experimental modifications to donor, recipient, or graft all demonstrated short-graft survivals (31 d). Chimerism levels without bone marrow infusion were transient and minimal when detected and were not associated with prolonged survival. Donor bone marrow infusion increased levels of chimerism but resulted in alloantibody production and did not improve graft survival. Conclusions.: VCA graft survival is significantly reduced compared with previously reported VCA with VBM transplants (348 d; P = 0.01) when the hematopoietic niche is removed, altered, or destroyed via irradiation, depletion, or topographical rearrangement. These experimental manipulations resulted in similar outcomes to VCA grafts without cotransplanted VBM (25 d). These data support the presence of a radiosensitive, T-cell population within the VBM compartment not reconstituted by reinfusion of bone marrow cells.


  • Open Access

    The demise of islet allotransplantation in the United States: A call for an urgent regulatory update

    by Piotr Witkowski, Louis H. Philipson, Dixon B. Kaufman, Lloyd E. Ratner, Marwan S. Abouljoud, Melena D. Bellin, John B. Buse, Fouad Kandeel, Peter G. Stock, David C. Mulligan, et al.


  • Open Access

    Financial incentives versus standard of care to improve patient compliance with live kidney donor follow-up: protocol for a multi-center, parallel-group randomized controlled trial

    by Macey L. Levan, Madeleine M. Waldram, Sandra R. DiBrito, Alvin G. Thomas, Fawaz Al Ammary, Shane Ottman, Jaclyn Bannon, Daniel C. Brennan, Allan B. Massie, Joseph Scalea, et al.

    Background: Live kidney donors (LKDs) account for nearly a third of kidney transplants in the United States. While donor nephrectomy poses minimal post-surgical risk, LKDs face an elevated adjusted risk of developing chronic diseases such as hypertension, diabetes, and end-stage renal disease. Routine screening presents an opportunity for the early detection and management of chronic conditions. Transplant hospital reporting requirements mandate the submission of laboratory and clinical data at 6-months, 1-year, and 2-years after kidney donation, but less than 50% of hospitals are able to comply. Strategies to increase patient engagement in follow-up efforts while minimizing administrative burden are needed. We seek to evaluate the effectiveness of using small financial incentives to promote patient compliance with LKD follow-up. Methods/design: We are conducting a two-arm randomized controlled trial (RCT) of patients who undergo live donor nephrectomy at The Johns Hopkins Hospital Comprehensive Transplant Center (MDJH) and the University of Maryland Medical Center Transplant Center (MDUM). Eligible donors will be recruited in-person at their first post-surgical clinic visit or over the phone. We will use block randomization to assign LKDs to the intervention ($25 gift card at each follow-up visit) or control arm (current standard of care). Follow-up compliance will be tracked over time. The primary outcome will be complete (all components addressed) and timely (60 days before or after expected visit date), submission of LKD follow-up data at required 6-month, 1-year, and 2-year time points. The secondary outcome will be transplant hospital-level compliance with federal reporting requirements at each visit. Rates will be compared between the two arms following the intention-to-treat principle. Discussion: Small financial incentivization might increase patient compliance in the context of LKD follow-up, without placing undue administrative burden on transplant providers. The findings of this RCT will inform potential center- and national-level initiatives to provide all LKDs with small financial incentives to promote engagement with post-donation monitoring efforts. Trial registration: ClinicalTrials.gov number: NCT03090646 Date of registration: March 2, 2017 Sponsors: Johns Hopkins University, University of Maryland Medical Center Funding: The Living Legacy Foundation of Maryland